Johnson & Johnson (JNJ) shares dropped nearly 5% after a U.S. Bankruptcy Court in Texas denied a bankruptcy plan proposed by its subsidiary, Red River Talc. This plan was part of J&J's legal strategy to contain thousands of lawsuits alleging that its talc-based products caused cancer. The denial essentially forces the healthcare giant back into the traditional tort system—court by court, case by case. Instead of appealing the decision, J&J stated it intends to return to the tort system to "challenge and defeat meritless talc claims." While some investors viewed the ruling as a blow to the company’s legal defenses, others (myself included) are asking: is this a short-term dip worth capitalizing on? Breaking It Down The failed bankruptcy maneuver was meant to limit liability and streamline payouts. Without it, the company faces a more protracted—and potentially costlier—battle. However, Johnson & Johnson isn't a fragile upstart. It has over $360 billi...
A periodical exploring the art of investing, financial knowledge, and the stories that shape a meaningful life.